Blood disorders
Lymphoma in Changchun
长春 淋巴瘤
4 hospitals in Changchun
Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Changchun may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 24 papers led
- 10 papers ledNo open trial led
- 6 papers ledNo open trial led
- 0 papers ledNo open trial led
Lymphoma in every city Changchun on the disease page, with the national map
open trials on lymphoma with a hospital in Changchun
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Changchun as lead sponsor or study site. 3 of them are led by a hospital in Changchun. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07409428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou
- RecruitingExploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07441993
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Jinan, Nanchang, Nantong, Tianjin, Wuhan, Zhengzhou
- RecruitingChidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07493109
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
- RecruitingChidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07493148
Age 70 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
- RecruitingEfficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study
- Phase
- Phase 4
- Started
- 2026-10
- Posted
- Registry
- NCT07908888
Age 65 years to Not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06717347
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen
- RecruitingClinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06829771
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou
- RecruitingA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT06973187
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Harbin, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xining, Xuzhou, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07082686
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07124936
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shenyang, Suzhou, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07154264
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nantong, Shenyang, Wuhan, Yichang, Zhengzhou
- RecruitingA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07189065
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingAn Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07200375
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingA Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07350850
Age 18 years to Not stated (registered criteria)
Led by Tongji Hospital; 2 listed hospitals as study sitesChangchun, Fuzhou, Wuhan
- RecruitingA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06363994
Age 60 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06378138
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi
- RecruitingEvaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06521255
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou
- RecruitingLinperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)
- Phase
- Phase 1/Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06592170
Age 18 years to Not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT07234162
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT06084936
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou
- RecruitingA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06136559
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Phase
- Phase 2/Phase 3
- Started
- 2022-01
- Posted
- Registry
- NCT05139017
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Luoyang, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- Phase
- Phase 1/Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05294731
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou
- RecruitingRituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma
- Phase
- N/A
- Started
- 2022-12
- Posted
- Registry
- NCT06946407
Age Not stated to 60 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Phase
- Phase 2
- Started
- 2021-04
- Posted
- Registry
- NCT04728893
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingR-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden
- Phase
- N/A
- Started
- 2021-08
- Posted
- Registry
- NCT05040555
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
- RecruitingA Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
- Phase
- Phase 1
- Started
- 2021-03
- Posted
- Registry
- NCT06189391
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Jinan, Nanchang, Shanghai, Shijiazhuang, Tianjin, Xiamen, Zhengzhou
- RecruitingStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
- Phase
- Phase 1/Phase 2
- Started
- 2020-08
- Posted
- Registry
- NCT04494503
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan
- Not yet recruitingA Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07525817
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
- Not yet recruitingOrelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07677813
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Changchun
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Hospital of Changchun University of Chinese Medicine长春中医药大学附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | 6 | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | 1 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | |
| China-Japan Union Hospital, Jilin University吉林大学白求恩第三医院(中日联谊医院) | 0 | none | 21 | 22 | 31 | 14 | 51 | 22 | none | 0 | 0 | 13 | 1 | 1 | 0 | 4 | none | none | none | 10 | none | none | none | none | none | 3 | none | 2 | 2 | none | none | 15 | 4 | 2 | none | 0 | none | 1 | none | 1 | 0 | none | none | none | 0 | none | 0 | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | |
| First Hospital of Jilin University吉林大学第一医院 | 3 | 5 | 761 open | 417 open | 1121 open | 27 | 772 open | 561 open | 1 | 3 | 0 | 17 | 0 | 7 | 2 | 174 open | 0 | 2 | 4 | 243 open | none | 0 | 2 | 1 | none | 11 | none | 1 | 4 | 2 | none | 202 open | 9 | 2 | 5 | 2 | none | 1 | none | 2 | 0 | 1 | none | 0 | 3 | 0 | 71 open | 1 | none | 0 | 11 | 1 | none | none | none | none | 0 | none | none | none | none | |
| Jilin Cancer Hospital吉林省肿瘤医院 | none | 0 | 4 | 0 | 39 | none | 2 | 1 | none | none | none | none | 0 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jilin Heart Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jilin Province FAW General Hospital吉林省一汽总医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jilin Province People's Hospital吉林省人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Hospital of Jilin University吉林大学第二医院 | 0 | 1 | 15 | 17 | 37 | 8 | 20 | 10 | none | 1 | none | 11 | 1 | 1 | 0 | 4 | none | none | none | 6 | none | none | none | none | none | none | 5 | none | none | none | none | 123 open | 2 | 1 | none | 0 | none | 7 | none | 2 | none | none | 1 | none | 1 | 0 | 7 | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Changchun.
- Nasopharyngeal carcinoma 0
- Hepatocellular carcinoma 21
- Stomach cancer 22
- Lung cancer 31
- Pancreatic cancer 14
- Breast cancer 51
- Glioma 22
- Retinoblastoma 0
- Chordoma 0
- Osteosarcoma 13
- Gastrointestinal stromal tumour 1
- Neuroblastoma 1
- Ewing sarcoma 0
- Multiple myeloma 4
- Lymphoma 10
- Neuromyelitis optica spectrum disorder 3
- Myasthenia gravis 2
- Moyamoya disease 2
- Coronary heart disease 15
- Congenital heart disease 4
- Scoliosis 2
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 1
- Spinal muscular atrophy 0
- Behçet disease 0
- IgA nephropathy 0
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 1
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 5
- Hepatocellular carcinoma 761 open
- Stomach cancer 417 open
- Lung cancer 1121 open
- Pancreatic cancer 27
- Breast cancer 772 open
- Glioma 561 open
- Hepatoblastoma 1
- Retinoblastoma 3
- Chordoma 0
- Osteosarcoma 17
- Gastrointestinal stromal tumour 0
- Neuroblastoma 7
- Ewing sarcoma 2
- Multiple myeloma 174 open
- B-cell acute lymphoblastic leukaemia 0
- Aplastic anaemia 2
- Haemophagocytic lymphohistiocytosis 4
- Lymphoma 243 open
- Haemophilia A 0
- Atypical haemolytic uraemic syndrome 2
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 11
- Myasthenia gravis 1
- Moyamoya disease 4
- Wilson disease 2
- Coronary heart disease 202 open
- Congenital heart disease 9
- Scoliosis 2
- Anti-NMDA receptor encephalitis 5
- Takayasu arteritis 2
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 2
- Spinal muscular atrophy 0
- Fabry disease 1
- Duchenne muscular dystrophy 0
- Behçet disease 3
- Alport syndrome 0
- IgA nephropathy 71 open
- Gaucher disease 1
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 11
- Primary sclerosing cholangitis 1
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 0
- Oesophageal squamous cell carcinoma 1
- Hepatocellular carcinoma 15
- Stomach cancer 17
- Lung cancer 37
- Pancreatic cancer 8
- Breast cancer 20
- Glioma 10
- Retinoblastoma 1
- Osteosarcoma 11
- Gastrointestinal stromal tumour 1
- Neuroblastoma 1
- Ewing sarcoma 0
- Multiple myeloma 4
- Lymphoma 6
- IgG4-related disease 5
- Coronary heart disease 123 open
- Congenital heart disease 2
- Scoliosis 1
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 7
- Amyotrophic lateral sclerosis 2
- Pompe disease 1
- Behçet disease 1
- Alport syndrome 0
- IgA nephropathy 7
- Primary biliary cholangitis 2
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lymphoma.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Changchun on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.